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Received 10 May 2007; accepted 3 June 2007Abstract Regeneration of the myocardium by transplantation of cardiomyocytes is an emerging therapeutic strategy. Human
embryonic stem cells (HESC) form cardiomyocytes readily but until recently at low efficiency, so that preclinical studies on
transplantation in animals are only just beginning. Here, we show the results of the first long-term (12 weeks) analysis of the
fate of HESC-derived cardiomyocytes transplanted intramyocardially into healthy, immunocompromised (NOD-SCID) mice and in
NOD-SCID mice that had undergone myocardial infarction (MI). Transplantation of mixed populations of differentiated HESC
containing 20–25% cardiomyocytes in control mice resulted in rapid formation of grafts in which the cardiomyocytes became
organized and matured over time and the noncardiomyocyte population was lost. Grafts also formed in mice that had undergone
MI. Four weeks after transplantation and MI, this resulted in significant improvement in cardiac function measured by magnetic
resonance imaging. However, at 12 weeks, this was not sustained despite graft survival. This suggested that graft size was still
limiting despite maturation and organization of the transplanted cells. More generally, the results argued for requiring a
minimum of 3 months follow-up in studies claiming to observe improved cardiac function, independent of whether HESC or other
(adult) cell types are used for transplantation.
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The adult human heart has a minimal ability to regenerate
myocardium, so that the loss of viable cardiomyocytes in
cardiac disease, precipitated by myocardial infarction (MI),
leads to heart failure. Cell transplantation for cardiomyocyte
replacement represents a potential opportunity for a new
treatment strategy (Dimmeler et al., 2005; van Laake et al.,
2006a). The transplantation of adult (bone marrow) stem
cells has already entered clinical trials, based on reports of
improved cardiac function in animals (Orlic et al., 2001a,b),
although the robustness of these results has been questioned
and there is no evidence that the transplanted cells form
cardiomyocytes or contribute to the myocardium (Balsam et
al., 2004; Murry et al., 2004; Nygren et al., 2004). Fusion of
bone marrow stem cells with cardiomyocytes in the heart in
situ andmisinterpretation of autofluorescence artifacts from
dying cells and macrophages have been proposed as
explanations for their apparent transdifferentiation (Balsam
et al., 2004; Brazelton and Blau, 2005; Murry et al., 2004;
Nygren et al., 2004). The functional improvements reported
may have resulted from cell-independentmechanisms and/or
neovascularization (Fazel et al., 2006). The outcomes of
clinical trials with various bone marrow fractions have so far
been inconsistent and suggested mainly modest, temporary
enhancement of cardiac function (Assmus et al., 2006; Lunde
et al., 2006; Rosenzweig, 2006; Schachinger et al., 2006). In
almost all preclinical experiments in rodents and larger
animals such as swine and sheep, follow-up has been limited
to short and mid-term, usually a maximum of 2 to 6 weeks
(Menard et al., 2005; Orlic et al., 2001a,b; Zhang et al.,
2007). Most investigators have found a positive effect of cell
transplantation post-MI at these early time points, indepen-
dent of whether bone marrow cells (BMCs), mesenchymal
stem cells, or mouse embryonic stem cells (mESCs) were used
and whether they were injected intravenously or intra-
myocardially. Beneficial effects have also been reported even
when transplanted cells were no longer detectable in the
myocardium (Iso et al., 2007; Muller-Ehmsen et al., 2006).
Human embryonic stem cells (HESCs) have clearly been
shown to have the capacity to differentiate into cardiomyo-
cytes in vitro (Kehat et al., 2001; Mummery et al., 2003;
Passier et al., 2005; Xu et al., 2002). We and others have
shown that HESC-derived cardiomyocytes (HESC-CM) have a
fetal rather than an adult phenotype, based on their
expression of sarcomeric proteins and electrophysiological
characteristics (He et al., 2003; Kehat et al., 2001; Mummery
et al., 2003). In previous reports, HESC-CM have also been
engrafted into uninjured rat hearts (Laflamme et al., 2005)
and in electrophysiologically silenced guinea pig and swine
hearts (Kehat et al., 2004; Xue et al., 2005). Cells were foundFigure 1 Tracking of grafted differentiated HESCs using multiple in
HES3-GFP in NOD-SCID mouse heart. (A, E) GFP, (B) hu-nuclei, (C, G)
spectra of transplanted differentiated HES3-GFP: (K) sharp peak
erythrocytes. (L) GFP, (M) DIC, (N) emission wavelength spectru
cardiomyocytes. (O) GFP, (P) DIC, (Q) emission wavelength spectra: br
with (S) GFP-antibody staining. (T) Overlay including topro-3, (U) do
wavelength spectra. Region of interest: circles in color matching s
transplantation. Scale bars, 20 μm.to survive and pace the recipient myocardium. However, the
long-term effects of transplantation, particularly whether
functional improvement and graft survival are sustained, are
not known.
Here, we describe results of the first long-term study of
HESC-CM in uninjured and infarcted mouse hearts. By immu-
nohistological and ultrastructural analysis of grafts over
time, we demonstrated that HESC-CM survive, integrate, and
mature in the host myocardium for at least 12 weeks. Mag-
netic resonance imaging (MRI) showed that HESC-CM trans-
plantation improved heart function after MI at 4 weeks, but
this was not sustained at 12 weeks, despite the continued
presence of healthy grafts.
Results
Tracking of transplanted human cells in the mouse
heart
We induced HESCs expressing green fluorescent protein
(GFP) ubiquitously (HES3-GFP; Costa et al., 2005; Doeven-
dans et al., 1996) to differentiate in serum-free medium as
described previously (Mummery et al., 2003; Passier et al.,
2005). We prepared single-cell suspensions containing 20–
25% cardiomyocytes from beating areas for injection.
Within 3 weeks of intramyocardial injection in NOD-SCID
mice, the differentiated cells had formed stable grafts,
enabling us to develop methods for unambiguous graft
identification at all other time points (2.5 days to 12
weeks) after transplantation, avoiding artifacts that easily
arise in these experiments (supplementary results and
Supplementary Fig. 1). The human origin of GFP-expressing
cells was confirmed by staining with antibodies recognizing
only human, and not mouse, nuclei and mitochondria in
matching patterns (Figs. 1A–1H). By analyzing wavelength
emission spectra, we could distinguish GFP fluorescence
from nonspecific autofluorescence of blood and dead cells,
which were also present in the graft area (Figs. 1I–1Q).
Finally, staining with anti-GFP antibody overlapped with
GFP epifluorescence, demonstrating that in the HES3-GFP
cell line, GFP was bright enough to be used as the primary
cell tracking marker (Figs. 1R–1U). All antibody isotype
controls were negative.
HESC-derived grafts are maintained in the mouse
heart for at least 12 weeks independent of fusion
with host cells
The superficial part of the grafts (close to the epicardium)
could be visualized in whole-mount hearts as islands of GFP-dependent methods. (A–H) Fluorescent staining of differentiated
topro-3, (D, H) overlay, (F) hu-mito. (I–K) Emission wavelength
at 515 nm. (I) GFP. (J) DIC. (L–N) Brightly autofluorescent
m: broad peak around 570 nm. (O–Q) Autofluorescent dead
oad peak around 550 nm. (R–U) (R) GFP epifluorescence overlaps
uble peak for GFP and Cy3 (peak emission at 570 nm) in emission
pectra curves. All images represent observations 3 weeks after
11HESC-derived cardiomyocytes in the mouse heart
Figure 2 Graft development and maintenance in the mouse heart. (A–F) Differentiated HES3-GFP graft in mouse heart 1 week after
transplantation. (A, D) Bright field, (B, E) GFP, (C, F) overexposure with filter for red fluorescence. (G–I) Graft 3 weeks after
transplantation. (H) GFP epifluorescence in halved heart, (I) cryosection of same area (green, GFP; red, α-actinin; blue, topro-3), (G)
HE staining of adjacent section. (J–O) Graft 12 weeks after transplantation. (J, M) Bright field, (K, N) GFP, (L, O) overexposure with
filter for red fluorescence. Scale bars, 250 μm.
12 L.W. van Laake et al.fluorescent cells, which remained detectable up to 12
weeks, the last time point examined (Figs. 2A–2F and 2J–
2O). Transverse division and sectioning of the hearts showed
transmural incorporation of HESC-CM in the left ventricularwall where the cells had been injected (Figs. 2G–2I). Since
all nuclei in GFP+ cells stained with human-nuclei antibody
(except those in metaphase, a known characteristic of the
antibody as indicated by the manufacturer), survival of the
Figure 3 Survival of differentiated HESCs in the mouse heart is independent of fusion with host cardiomyocytes. (A–C) All nuclei in
grafted GFP cells stain with hu-nuclei antibody (green, GFP; red, hu-nuclei; blue, topro-3). (D–I) One week after transplantation HES3-
GFP CM express only MLC2A (E) and no MLC2V protein (H). (D, G) GFP, (F, I) overlays including topro-3 (blue). Scale bars, 20 μm.
13HESC-derived cardiomyocytes in the mouse hearttransplanted cells was unlikely to be the result of fusion
between donor and host cells (Figs. 3A–3C). Further, HESC-
CM in vitro have an immature phenotype comparable to
early human fetal cardiomyocytes (Mummery et al., 2003).
Despite ventricular action potentials (Mummery et al.,
2003), HESC-CM express only myosin light chain 2A (MLC2A)
and not MLC2V protein in sufficient quantities to be
recognized by an antibody (Supplementary Fig. 2); mouse
ventricular cardiomyocytes, by contrast, express MLC2V
exclusively. This differential expression pattern, compatible
with differences described between human and mouse fetal
heart (Chuva de Sousa Lopes et al., 2006), was evident at all
early time points after transplantation; this again corrobo-
rated the improbability of cell fusion taking place on a large
scale (Figs. 3D–3I).
Selective survival of HESC-CM and proliferation of
transplanted cells
Since the injected cell preparations contained only 20–25%
cardiomyocytes, we examined the fate of HESC-CM versus
other cell types present in the injected suspensions after
transplantation. Over a period of 2.5 days to 10 weeks, an
increasing proportion of GFP-expressing cells with validated
emission spectra stained positive for cardiac markers; these
included cardiac α-actinin (Figs. 4A–4L), tropomyosin (data
not shown), and MLC2 (examples of staining in Figs. 3 and 6).The organization of the grafts improved from an incoherent
cluster of multiple cell types (Figs. 4A–4D) to more rod-
shaped cardiomyocytes aligned with the mouse myocardium
(Figs. 4E–4H). However, we also saw large clusters of grafted
cardiomyocytes in varying orientations at later time points
(Figs. 4I–4L). Concurrently, the number of cells with an
endoderm-like phenotype staining for cytokeratin 8/troma-1
(Figs. 4M–4P) rapidly decreased. No endothelial differentia-
tion from HESC-derived cells was found. Instead, blood
supply to the grafts seemed to be provided by mouse-derived
vessels through local angiogenesis (Figs. 4Q–4T and Supple-
mentary Movie 1). Quantification of cardiac marker versus
endodermal marker expression in grafted GFP cells con-
firmed the retention of cardiomyocytes and disappearance
of other cell types in the weeks after transplantation (Figs.
4U–4V). We next calculated the efficiency of the cell
transplantation as the ratio of GFP cells present at a given
time point to the total number of cells that were injected.
Overall, cell survival diminished over time, leaving a final
efficiency of only 2.3±0.6%, but the absolute number of
cardiomyocytes remained stable on the order of 10% (Figs.
5A–5C, Supplementary Table 1, and Supplementary Movie 2).
Thus, selective survival of cardiomyocytes rather than
(trans)differentiation of noncardiomyocytes would seem
the likely mechanism underlying the overrepresentation of
cardiomyocyte phenotype over time. Indeed, when we
injected HES3-GFP from nonbeating areas of HES3-GFP/
14 L.W. van Laake et al.END2 coculture, containing only very few cardiomyocytes,
we found no or only extremely small grafts after more than 3
weeks (n=12, data not shown).
We observed cell cycle activity in graft cells at all time
points, with a peak at 1 week posttransplantation, and in-creasingly predominantly in cardiomyocytes parallel to the
rise in representation of the cardiomyocyte phenotype over
time (Figs. 5D–5M). We did not observe any HESC-related
tumor formation at any time point in any organ (data not
shown).
Figure 5 Quantification of transplantation efficiency and proliferation of grafted cells. (A, B) The majority of the grafted cells are
single-nucleated (green, GFP; red, WGA-TRITC as a membrane marker; blue, topro-3). (C) Percentage of cell survival at successive time
points for all cells (broken line) and CM specifically (solid line; assuming the injected cell preparation contained 20% CM). *Pb0.05 for 2.5
days vs 3 weeks and 2.5 days vs 10weeks. (D–K) Ki-67 staining of HES3-GFP CM at (D–G) 2.5 days and (H–K) 10weeks after transplantation.
(D, H) GFP, (E, I) Ki-67, (F, J) α-actinin, (G, K) overlays. (L) Proportion of GFP cells positive for Ki-67. **Pb0.01 for 2.5 days vs 1 week;
##Pb0.01 for 1 week vs 10weeks andPb0.05 for 1 week vs 3weeks; †Pb0.05 for 3 weeks vs 10weeks. (M) Percentage of Ki-67-positiveGFP
cells that express cardiac markers. **Pb0.01 for 2.5 days vs 1 week and for 2.5 days vs 10 weeks and Pb0.05 for 2.5 days vs 3 weeks. Scale
bars, 20 μm.
15HESC-derived cardiomyocytes in the mouse heartMaturation of HESC-CM in vivo
In beating areas in vitro, α-actinin-positive HESC-CM express
smooth muscle actin (SMA), indicating their immaturity (Cle-Figure 4 Selective survival of HESC-CM and loss of endodermal deri
3 weeks (E–L) after transplantation of HES3-GFP-derived cells. (A, E
(blue), (D, H) DIC, (L) HE staining of section adjacent to (I–K). (M–
transplantation. (M) GFP, (N) troma-1, (O, P) overlays of GFP, troma-1,
(Q) GFP, (R) PECAM-1, (S) overlay including topro-3 (blue), (T) DIC. (U)
between 2.5 days and 10 weeks. (V) Proportion of endoderm cells decl
days vs 10 weeks; ##Pb0.01 for 1 week vs 3 weeks and 1 week vs 10ment et al., 2007; Ya et al., 1997) (Supplementary Fig. 2).
Within 1 week of transplantation, however, SMA was com-
pletely downregulated (Figs. 6A–6D and Table 1). In addition,
3 weeks after transplantation all grafted GFP cells stillvatives. (A–L) Sarcomeric α-actinin staining at 2.5 days (A–D) and
, I) GFP, (B, F, J) α-actinin, (C, G, K) overlays including topro-3
P) Identification of HES3-GFP-derived endoderm 1 week after
and topro-3 (blue). (Q–T) Only host-derived vessels within graft.
The proportion of GFP cells positive for cardiacmarkers increases
ines. **Pb0.01 for 2.5 days vs 1 week, 2.5 days vs 3 weeks, and 2.5
weeks; ††Pb0.01 for 3 weeks vs 10 weeks. Scale bars, 20 μm.
16 L.W. van Laake et al.expressed MLC2A, as in vitro and at 1 week posttransplanta-
tion (Fig. 3), but many of them had become double positive for
MLC2A and MLC2V (Figs. 6E–6J). This maturation continuedFigure 6 HESC-CM mature in vivo. (A–D) HESC-CM lose SMA expre
vessel), (C) α-actinin, (D) overlay. (E–J) Three weeks after transplant
proteins (adjacent sections). (E, H) GFP, (F) MLC2A, (I) MLC2V, (G
transplantation most HESC-CM express either MLC2A or MLC2V (adja
including topro-3 (blue), (N, R) DIC. Scale bars, 20 μm.and at 10 weeks we only occasionally observed double-positive
cells; most GFP cells were either MLC2A positive or had
become MLC2V positive (Figs. 6K–6R and Table 1).ssion from 1 week after transplantation. (A) GFP, (B) SMA (red,
ation HES3-GFP CM express only MLC2A or both MLC2A and MLC2V
, J) overlays including topro-3 (blue). (K–R) Ten weeks after
cent sections). (K, O) GFP, (L) MLC2A, (P) MLC2V, (M, Q) overlays
Table 1 Maturation of HESC-CM in vivo after transplantation
in the mouse heart
MLC2 SMA Cx-43 Desmoplakin
In vitro A + – or ± +
2.5 days A ± – ±
1 week A – – or ± ± or +
3 weeks A or A and V – ± + (hu-hu)
10 weeks A and V or
A or V
– ± or +
(hu-hu)
+ (hu-hu) or
+ (hu-ms)
17HESC-derived cardiomyocytes in the mouse heartFunctional coupling after transplantation
As the HESC-CM were injected as single cells, they would
need to reestablish intercellular contacts to form a func-
tional syncytium. Connexin-43 (Cx-43), normally located at
gap junctions betweenmature cardiomyocytes (Peters et al.,
1994), was upregulated over time. Up to 3 weeks after
transplantation Cx-43 was present, but not in the clear pat-
tern of gap-junctional structures (Figs. 7A–7D). Only after 10
weeks did we see gap junctions with Cx-43 between adjoined
HESC-CM (Figs. 7E–7H and Table 1). The organization of
desmoplakin, a desmosomal protein, was already clear at 3
weeks after transplantation and we observed some desmo-
some formation sporadically between HESC-CM and mouse
cardiomyocytes (Figs. 7I–7Tand Table 1). In agreement with
the antibody staining, electron microscopy demonstrated
that HESC-CM were connected to each other via desmo-
somes, but were usually separated from mouse cardiomyo-
cytes by a thin (0.5–20 μm) layer of extracellular matrix
(Figs. 7U–7V).
HESC-CM improved mid-term, but not long-term,
heart function after myocardial infarction
To assess the effects of HESC-CM on cardiac function, we
injected 1×106 cells from beating areas of HES3-GFP (HESC-
CM group) or differentiated non-CM cells from the same
origin (non-CM group) into mice with acute MI and measured
heart function after 2 days (acute phase), 4 weeks (mid-
term), and 12 weeks (long term) by MRI as described pre-
viously (van Laake et al., 2006b). Twelve weeks after in-
jection, we found GFP-fluorescent grafts in all mouse hearts
that received HESC-CM and in none of the non-CM
transplanted hearts (Figs. 8A–8C). GFP+ cells were mostly
localized in the border zone of the infarct but also in the
middle of the infarct surrounded by scar tissue (Figs. 8A–
8C). Although we created large infarcts to obtain maximum
reproducibility, 12-week survival of the mice was N80% and
similar in the two experimental groups of mice (Fig. 8D).
Heart function 2 days post-MI was equal in the HESC-CM and
non-CM groups, showing a comparable baseline situation.
Four weeks after MI, HESC-CM mice had a significantly
greater ejection fraction (EF) than non-CM mice. Stroke
volume (SV) was also larger, resulting from improved
contractility because dilatation was even slightly less
pronounced in HESC-CM mice. The natural reduction in EF
from 2 days to 4 weeks post-MI (serial measurements in
each mouse) was similarly attenuated in the HESC-CMgroup. Nevertheless, at 12 weeks after induction of MI and
cell transplantation, these beneficial effects of cardiomyo-
cytes were not retained, whether we compared the
absolute 12 weeks or the change from 2 days to 12 weeks
(Figs. 8E–8Q, Supplementary Table 2, and Supplementary
Movies 3–8).Discussion
We have demonstrated that HESC-CM can survive, integrate,
and mature after intramyocardial injection in immunodefi-
cient mice, presenting for the first time a series with follow-
up of up to 12 weeks. The importance of this extended
follow-up was emphasized by the significant beneficial
effect of HESC-CM on heart function after MI, when analysis
was at mid-term, but its failure to be sustained when analysis
was long term.
In any cell transplantation study, great care should be
taken to avoid misinterpretation of data arising from arti-
facts that can occur as a consequence of injury (by needle
manipulation or infarction) and inflammation of the tissue,
potential immune activation, and cell death (Balsam et al.,
2004; Brazelton and Blau, 2005; Burns et al., 2006; Murry et
al., 2004; Nygren et al., 2004). We excluded nonspecific
staining and autofluorescence and circumvented the need
for indirect tracking methods such as dye labeling by using
the HES3-GFP cell line Envy, which maintains strong GFP
fluorescence in all undifferentiated as well as differen-
tiated cells (Costa et al., 2005). Combining this genetic
tracking with emission finger printing and human-specific
antibody staining, we confirmed the presence of cells of
human origin in the mouse heart for at least 12 weeks after
transplantation. This is by far the longest follow-up that
has been reported to date for HESC transplantation studies
in heart. No addition of matrix or prosurvival factors was
required to sustain grafts even as long as 12 weeks after MI,
contrary to findings by others (Laflamme and Murry,
abstract, American Heart Association Scientific Sessions,
Chicago, 2006).
The immaturity of the HESC-CM generated in our END2
coculture system, with a phenotype resembling that of
end first-trimester human fetal cardiomyocytes (Chuva de
Sousa Lopes et al., 2006; Passier et al., 2005), may
contribute to the reasonably good graft survival that was
essentially independent of fusion with host cardiomyo-
cytes (Soonpaa et al., 1994). Transplanted fetal cardio-
myocytes have been shown by others to survive and
integrate much better than primary adult cardiomyocytes
into adult myocardium (Reinecke et al., 1999) and have a
better capacity for proliferation, just as we observed in
the HESC-CM grafts. However, in terms of long-term
compatibility (for example, electrophysiological match-
ing), a more mature phenotype would eventually be
required. It was therefore encouraging that the HESC-CM
matured in vivo after transplantation, even in a xenotrans-
plantation model in which the paracrine, structural, and
mechanical factors may not be optimally suited to meet the
needs of human cardiomyocytes. Nevertheless, these factors
were apparently sufficient to result in selective survival of
cardiomyocytes and loss of other differentiated HESC from
the END2 coculture system, in accordance with a previous
18 L.W. van Laake et al.report on transplantation of HESC-derived cells in rats
(Laflamme et al., 2005). However, differentiated cultures
of HESC arising from END2 coculture are, for example, de-
void of neural cells (Beqqali et al., 2006); we cannot there-
fore exclude the possibility that some HESC derivatives
would be able to escape a selective survival mechanism, sothat efforts to derive pure cardiomyocyte populations are
still justified.
The maturation of HESC-CM observed here was evident
not only from the morphological appearance of cells within
the graft, which showed improved sarcomeric organization
and alignment within the host myocardium over time, but
19HESC-derived cardiomyocytes in the mouse heartalso from downregulation of markers associated with im-
maturity (SMA and MLC2A), upregulation of markers of more
mature cells (MLC2V, Cx-43), and increased intercellular
contacts (desmosomes and gap junctions).
The mechanisms by which selective survival and matura-
tion of HESC-CM in vivo are accomplished have yet to be
determined, but may be based on integrin-mediated cell–
cell and cell–extracellular matrix interactions, also includ-
ing stretch and stiffness (Baharvand et al., 2005; Chen et al.,
2007; Dallabrida et al., 2005; Macfelda et al., 2007; Zhuang
et al., 2000). Furthermore, paracrine factors (Song et al.,
2007) and electrophysiological signals (Ellison et al., 2007)
may play an additional role.
Selection of HESC-CM from mixed differentiated cell
populations has recently been described (Huber et al., 2007)
and will certainly be invaluable for in vitro studies, but it
remains to be seen whether pure cardiomyocyte populations
would be preferable to mixed populations with respect to
transplantation efficiency. For example, co-injection of fib-
roblasts with mESCs greatly improved survival and restora-
tion of cardiac function compared to mESCs alone (Kolossov
et al., 2006).
HESC-CM have been reported previously after transplan-
tation in the heart to drive the myocardium electrically when
it has been electrophysiologically silenced or slowed down,
thus functioning as biological pacemakers (Kehat et al.,
2004; Xue et al., 2005). This implies that HESC-CM can func-
tionally couple to the host myocardium. We found that HESC-
CM generally form intragraft desmosomes and gap junctions,
but only rarely were they connected to mouse cardiomyo-
cytes by desmosomes, even in 12-week grafts. More often, a
thin layer of extracellular matrix separated donor and host
cells. Even so, this does not exclude the possibility of ex-
tensive functional coupling since electrophysiological signal-
ing can be conducted through much thicker layers of fibrotic
tissue (Gaudesius et al., 2003). Of note is the enormous
difference between mouse and human heart rates: a mouse
heart may beat 400–600 times per minute, whereas in
humans, the rate is 60–100 beats per minute. The question
therefore arises whether matured human cardiomyocytes
could actually be expected to couple functionally to adult
mouse cardiomyocytes in vivo. Nevertheless, even though
we found no evidence for arrhythmias induced by the trans-
planted cells, the (ar)rhythmogenic potential of HESC-CM in
infarcted hearts should be investigated in larger animals
models with slower heart rates than the mouse. A note of
caution is also warranted with respect to the absence of
evidence for tumor formation, particularly teratomas or
teratocarcinomas, in the present study. While it is reassuring
that the differentiation method used did not result in resi-Figure 7 HESC-CM functionally couple to each other and occasiona
not in a gap-junctional pattern. (A) GFP, (B) Cx-43, (C) overlay, (D) o
junctions between donor cells 10 weeks after transplantation (indica
(blue), (H) DIC. (I–T) Desmoplakin is unorganized at 1 week after tran
weeks (M–P), and occasionally forms connections between donor and
(J, N, R) desmoplakin, (K, O) laminin as a marker of cell boundaries,
including topro-3 (blue) and line scans in x and y directions. Bars, 20 μ
(right) cardiomyocyte 12 weeks after transplantation. Black dots re
extracellular matrix. Scale bar, 500 nm. (V) Two human cardiomyocy
(n) nucleus; arrowheads, desmosome. Scale bar, 200 nm.dual expression of stem cell markers at the time of trans-
plantation or teratomas in the heart or elsewhere, even in
SCID mice (Thomson et al., 1998) without preselection of
cardiomyocytes, reported as essential when transplanting
mESC-derived cardiomyocytes (Kolossov et al., 2006), xeno-
transplantation may be less likely to induce teratomas than
intraspecies transplantations (Erdo et al., 2003).
In our study, immune rejection was prevented by using
NOD-SCID mice. In preliminary experiments with wild-type
mice (data not shown) we found no evidence for a major
immune privilege of transplanted differentiated HESCs com-
pared to adult progenitor cells (van Laake et al., 2006b):
immune suppression by the cyclosporin-analogue Tacrolimus
was necessary to avoid rejection, but daily injections and the
small therapeutic range of the agent made its use not
feasible for studies with long-term follow-up. HESCs, how-
ever, may be suitable for immunogenicity-reducing strate-
gies, including induction of tolerance in the recipient, or
HLA-matched transplantation from stem cell banks (Drukker
and Benvenisty, 2004; Zijlstra et al., 1990).
Since in light of their unambiguous cardiac phenotype,
fetal characteristics, and selective survival in the adult
mouse heart HESC-CM seemed to be a promising cell source
for cardiac regeneration, we investigated this potential cap-
acity in a mouse model of myocardial infarction. However,
because multiple cell types have now been shown to induce
short-term improvement in cardiac function in this MI model,
we anticipated that there may be beneficial effects of any
cell type (Merx and Weber, abstract, World Congress of
Cardiology, Barcelona, 2006). To assess specifically the
effects of additional cardiomyocytes in the infarcted myo-
cardium, we injected differentiated non-CM as a control.
Serial measurements by high-resolution MRI scanning enab-
led us to follow the heart function of each mouse at 2 days, 4
weeks, and 12 weeks after MI. Despite the hostile ischemic
environment in which the cells were injected, small but
clearly visible grafts were present in all hearts 12 weeks after
treatment with HESC-CM, reflecting the relative robustness
of these cells when transplanted in the heart.
Reduction of contractile capacity, indicated by EF, and
dilation of the infarcted left ventricular (LV) wall, indicated
by increased end-diastolic volume (EDV), are part of the
natural course of events after MI (Lutgens et al., 1999). SV
may also be reduced, depending on the ratio between dila-
tion and impaired contraction. Remarkably, transplantation
of HESC-CM after MI resulted in a significantly better EF and
SV at 4 weeks post-MI compared to non-CM-transplanted
controls. Also when the reduction of these parameters from 2
days to 4 weeks was analyzed, the HESC-CM-treated mice
had an unmistakably better outcome than controls. However,lly to mouse CM. (A–D) Cx-43 is present in 3-week-old grafts, but
verlay including topro-3 (blue). (E–H) Relocation of Cx-43 to gap
ted by arrows). (E) GFP, (F) Cx-43, (G) overlay including topro-3
splantation (I–L), is present in desmosomes within the graft at 3
host cells at 10 weeks (indicated by arrows) (Q–T). (I, M, Q) GFP,
(L, P) overlays, (S) overlay including topro-3 (blue), (T) overlay
m. (U) Electron microscopic image of a mouse (left) and a human
present immunogold labeling of GFP; (m) muscle fibers, (ECM)
tes in a graft after 12 weeks. Black dots, GFP; (m) muscle fibers;
Figure 8 Transplantation of HESC-CM after MI preserves mid-term heart function. (A–C) HES3-GFP-derived graft in mouse heart 4
weeks after LAD ligation and cell transplantation. (A) Bright field, (B) GFP, (C) overexposure with filter for red fluorescence. Scale bars,
250 μm. (D) Survival curves ofmice that received CMor non-CM after MI. (E–P) MR images of infarctedmouse hearts. (E–H) 4weeks after
MI and CM injection, (I–L) 4 weeks after MI and non-CM injection, (M–P) 12 weeks after MI and cell injection. (E, F, I, J, M, N) 4-chamber
view, (G, H, K, L, O, P) short-axis view, (E, I, M, G, K, O) end-diastolic, (F, J, N, H, L, P) end-systolic. Scale bars, 1 cm. (Q) EF, SV, and EDV
at 2 days, 4 weeks, and 12 weeks after MI and cell transplantation (repeated measurements) and relative change over time. *Pb0.05.
20 L.W. van Laake et al.at 12 weeks post-MI there was no longer a difference in EF
and SV between the two groups, although there was some
evidence of a sustained antiremodeling effect (less dilationand compensatory hypertrophy in the HESC-CM group;
supplementary results). Hence, HESC-CM had only tempora-
rily preserved heart function after MI. The beneficial mid-
21HESC-derived cardiomyocytes in the mouse heartterm effect may have been caused by paracrine factors from
the transplanted HESC, advantageous effects of inflamma-
tion, passive support, or actual contribution of the grafted
cells to contraction. It seems likely that for long-term im-
provement, larger grafts, consisting of functional and integ-
rated cardiomyocytes, would be required.
Comparing these results to previous data in mice using
BMCs that have already been transferred to clinical trials
(Assmus et al., 2006; Lunde et al., 2006; Rosenzweig, 2006;
Schachinger et al., 2006), it is of note that the extent of the
transient mid-term improvement we report here was com-
parable to that in several of these BMC studies, in which the
effects were generally unrelated to cellular engraftment and
long-term data are lacking (Templin et al., 2006; Uemura et
al., 2006; Yoshioka et al., 2005).
It remains to be determined how precisely these experi-
ments using a MI model in mice can be translated to patients
and whether they will benefit from such therapeutic
interventions of which the effects are substantial but never-
theless, at present, transient. Sustained enhancement of
heart function and prevention of heart failure should be the
Holy Grail in preclinical studies just as in translation to the
clinic. We show here that mid-term results may differ con-
siderably from and not predict long-term outcome. As a con-
sequence, reported short- and mid-term functional improve-
ments by any cell type should be reevaluated, raising the bar
for this field of research.
Taken together, the results showed that intramyocardially
transplanted HESC-CM are able to integrate and mature in
vivo in the myocardium of adult mice. HESC-CM also survive
in infarcted hearts for at least 12 weeks and improve heart
function at 4 weeks, but not 12 weeks, post-MI in the current
application, demonstrating the requirement for long-term
follow-up in all cardiac cell transplantation studies. Alter-
native transplantation protocols with larger numbers of car-
diomyocytes, multiple grafts, or methods to prevent cells
eluting into the circulation after transplantation could even-
tually lead to the realization of further and sustained
enhancement of heart function post-MI.Methods
Cell culture, differentiation, and dissociation
HES3-GFP cells (Costa et al., 2005) were cultured and in-
duced to form cardiomyocytes by coculture with END2 cells
(Mummery et al., 2003; Passier et al., 2005). This procedure
consistently gives rise to beating areas within 12 days of
culture. Beating areas consist of approximately 20–25% CM
and 75–80% endo- or other mesodermal derivates (Beqqali et
al., 2006; Passier et al., 2005). Beating areas were dissected
and dissociated with collagenase as described previously
(Moore et al., 2005; Passier et al., 2005). For control
experiments HES3-GFP cells were cultured on gelatin for 12
days. Under these conditions HES3-GFP cells underwent
spontaneous differentiation and did not form α-actinin-
positive cells after 12 days of culture (non-CM differentiated
control cells). Two hundred thousand (histology experi-
ments) or 1,000,000 cells (myocardial infarction and histol-
ogy experiments) were taken up in a final volume of 15 μl
fresh medium and used for transplantation.Animals and surgical procedures
All procedures involving experimental animals were ap-
proved by the Institute Animal Care Committee. Male NOD-
SCID mice (Charles River) 11–12 weeks of age were used for
all surgical procedures. Myocardial infarction was induced by
ligation of the left anterior descending coronary artery (LAD)
after left-sided thoracotomy, as described previously (van
Laake et al., 2006b). Ligation site was 1 mm below the left
auricle. Noninfarcted mice underwent the same procedure
but without ligation of the LAD. In the same operation, cells
were injected in the infarcted (MI mice; n=28) or healthy
(non-MI mice; n=36) myocardium of the free left ventricular
wall using an insulin syringe with incorporated 29-gauge
needle. The surgeon (L.v.L.) was blinded to the cell type
injected. At 2.5 days, 1 week, 3 weeks, 10 weeks, and 12
weeks after surgery, animals were euthanized and the hearts
were fixed and processed for cryosections as described
(Bajanca et al., 2004) with minor modification (sectioning in
Tissue-Tec). Lungs, liver, kidneys, spleen, and brain were
also examined for the presence of tumors.
MRI analysis of cardiac function
Two days, 4 weeks, and 12 weeks post-MI, magnetic reso-
nance images were acquired on a 9.4-T scanner (Bruker
Biospin GmbH, Rheinstetten, Germany) as described (van
Laake et al., 2006b); up to 10 short-axis slices were required
to image the dilated LV. Analysis was performed using Q-mass
digital imaging software (Medis, Leiden, The Netherlands) by
two independent blinded investigators (K.d.O. and L.v.L.).
Immunofluorescence
The complete GFP-cell-containing area of each heart was cut
into 6-μm cryosections, which were stained as described (van
Laake et al., 2006b) using the following antibodies and
dilutions: human nuclei 1:200 and human mitochondria 1:200
(both mouse; Chemicon), GFP 1:500 (rabbit; Abcam), α-
actinin 1:200 (rabbit; a kind gift from Elisabeth Ehler) or
1:800 (mouse; Sigma), tropomyosin 1:100 (mouse; Sigma),
troma-1 1:500 (rat; Developmental Studies Hybridoma
Bank), PECAM-1 1:100 (goat; Santa Cruz), MLC2A 1:100
(mouse; Synaptic Systems), MLC2V 1:50 (mouse; Synaptic
Systems), Ki-67 1:500 (rabbit; Abcam), smooth muscle actin
1:100 (rabbit; Abcam), connexin-43 1:200 (rabbit; Zymed),
desmoplakin (undiluted) (mouse; Progen Biotechnik), and
laminin 1:500 (rabbit; Sigma). Isotype controls (DAKO) were
performed for each class of antibody used. Cy3- and Cy5-
labeled secondary antibodies were from Jackson ImmunoR-
esearch Laboratories. WGA–TRITC (Sigma) was used for
membrane staining and topro-3 (1:1000) (Molecular Probes)
for nuclear counterstaining.
Microscopical analysis
A Leica MZ 16FA/DFC480 fluorescence microscope was used
to image whole hearts. Confocal scanning (with sequential
scanning for GFP with excitation laser 488 nm, Cy3/TRITC
with 543 nm, and Cy5 with 633 nm, respectively, to avoid
signal leakage) and emission wavelength spectrum analysis
22 L.W. van Laake et al.were performed on a Leica SP2 AOBS confocal laser scanning
microscope. For quantification of cell survival and expression
of phenotype markers, all GFP cells in at least nine evenly
distributed sections of each heart were counted by two
independent blinded investigators (J.M. and L.v.L.). Only
nuclei-containing cells were included to avoid double
counting in multiple sections. Nonfluorescent stainings
were imaged on a Nikon Eclipse E600/DXM1200 microscope.
For electron microscopy, hearts were perfusion- and
subsequently immersion-fixed with 2% formaldehyde/0.05%
glutaraldehyde in 100 mM phosphate buffer, pH 7.4, and
processed for Tokuyasu cryosectioning (Liou et al., 1996;
Tokuyasu, 1973). The 60-nm sections were labeled with anti-
GFP antibody (1:100) (rabbit; Abcam), which was detected
with protein A 10-nm gold (Utrecht Medical Center, Cell
Microscopy Center) (Slot and Geuze, 1981) and imaged with a
JEOL 1010 electron microscope at 80 kV.
Statistical analysis
Statistical significance was evaluated with SPSS version 11.5
for Windows using ANOVA or the Mann–Whitney U test with
correction for multiple-group comparisons by Bonferroni or
Median test, respectively, where applicable. Results are ex-
pressed as means±SEM. A value of Pb0.05 was considered
statistically significant.
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